Since activation of the BRD4-dependent gene expression is a core oncogenic driver for leukemia diseases [14,47,48,49,50,51,52,53] and Burkitt’s lymphoma [17], we also analyzed BRD4′s phosphorylation status in a number of leukemia and lymphoma cell lines [43]. This evidence concerns the gene BRD4 and Burkitt lymphoma.